These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

377 related items for PubMed ID: 34727333

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
    Rivkin A, Rybalov S.
    Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis.
    Shah ED, Kim HM, Schoenfeld P.
    Am J Gastroenterol; 2018 Mar; 113(3):329-338. PubMed ID: 29380823
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.
    Thomas RH, Luthin DR.
    Pharmacotherapy; 2015 Jun; 35(6):613-30. PubMed ID: 26016701
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Update on Pharmacotherapy for Irritable Bowel Syndrome.
    Munjal A, Dedania B, Cash B.
    Curr Gastroenterol Rep; 2019 Apr 25; 21(6):25. PubMed ID: 31025114
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Plecanatide for the treatment of constipation-predominant irritable bowel syndrome.
    Miner PB.
    Expert Rev Gastroenterol Hepatol; 2020 Feb 25; 14(2):71-84. PubMed ID: 31985305
    [Abstract] [Full Text] [Related]

  • 12. Novel pharmacological therapies for irritable bowel syndrome.
    Corsetti M, Whorwell P.
    Expert Rev Gastroenterol Hepatol; 2016 Jul 25; 10(7):807-15. PubMed ID: 26907518
    [Abstract] [Full Text] [Related]

  • 13. Management of irritable bowel syndrome with diarrhea: focus on eluxadoline.
    Jones J, Lembo A, Heidelbaugh J, Kuritzky L, Lacy B.
    Curr Med Res Opin; 2021 Apr 25; 37(4):567-578. PubMed ID: 33566707
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Evaluation of harm in the pharmacotherapy of irritable bowel syndrome.
    Shah E, Kim S, Chong K, Lembo A, Pimentel M.
    Am J Med; 2012 Apr 25; 125(4):381-93. PubMed ID: 22444104
    [Abstract] [Full Text] [Related]

  • 17. Recent advances in the pharmacological management of constipation predominant irritable bowel syndrome.
    Niewinna K, Zielińska A, Fichna J.
    Expert Opin Pharmacother; 2020 Jan 25; 21(1):73-84. PubMed ID: 31724881
    [Abstract] [Full Text] [Related]

  • 18. Tenapanor for constipation-predominant irritable bowel syndrome.
    Siddiqui S, Cash BD.
    Drugs Today (Barc); 2020 Mar 25; 56(3):203-210. PubMed ID: 32282867
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Review article: current and future treatment approaches for IBS with constipation.
    Liu JJ, Brenner DM.
    Aliment Pharmacol Ther; 2021 Dec 25; 54 Suppl 1():S53-S62. PubMed ID: 34927760
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.